source
- Par Health initiates voluntary recall of Argatroban injection after detecting particulate contaminantsPar Health USA announced a voluntary nationwide recall of its Argatroban Injection 250 mg/2.5 mL product, affecting 22 lots that have been distributed to hospitals and users. The recall was trigge…
- Syndax halts development of Niktimvo after Phase 2 failure in IPF trialSyndax announced it is stopping work on its experimental drug Niktimvo for idiopathic pulmonary fibrosis (IPF) after the compound did not meet its primary endpoints in a placebo-controlled Phase 2…Endpoints · 7d agoNegative readoutNegative